Charles Schwab
ALGS icon

Charles Schwab’s Aligos Therapeutics ALGS Stock Holding History

Charles Schwab’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,398
Closed -$183K – 3460
2025
Q2 		$183K Buy
25,398
+12,712
+100% +$76.1K ﹤0.01% 3381
2025
Q1 		$105K Sell
12,686
-1,600
-11% -$35.1K ﹤0.01% 3334
2024
Q4 		$569K Buy
14,286
+2,306
+19% +$44.6K ﹤0.01% 3107
2024
Q3 		$104K Buy
11,980
+10,725
+855% +$133K ﹤0.01% 3376
2024
Q2 		$11K Hold
1,255
– – ﹤0.01% 3610
2024
Q1 		$30.8K Hold
1,255
– – ﹤0.01% 3411
2023
Q4 		$20.8K Hold
1,255
– – ﹤0.01% 3478
2023
Q3 		$23.4K Hold
1,255
– – ﹤0.01% 3497
2023
Q2 		$30.5K Buy
+1,255
New +$33.7K ﹤0.01% 3503
2022
Q3 		– Sell
-2,959
Closed -$90K – 3510
2022
Q2 		$90K Sell
2,959
-1,994
-40% -$67.7K ﹤0.01% 3298
2022
Q1 		$267K Sell
4,953
-610
-11% -$48.8K ﹤0.01% 3246
2021
Q4 		$1.65M Buy
5,563
+150
+3% +$54.7K ﹤0.01% 2761
2021
Q3 		$2.1M Buy
5,413
+1,851
+52% +$732K ﹤0.01% 2695
2021
Q2 		$1.82M Buy
3,562
+698
+24% +$445K ﹤0.01% 2749
2021
Q1 		$1.63M Buy
2,864
+283
+11% +$188K ﹤0.01% 2709
2020
Q4 		$1.78M Buy
+2,581
New +$1.26M ﹤0.01% 2621

Other funds holding ALGS

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Charles Schwab's ALGS Position: Q3 2025 in Review

Charles Schwab sold out of Aligos Therapeutics (ALGS) in Q3 2025, closing a stake of 25,398 shares — an estimated $183K sold.

Charles Schwab first reported a position in ALGS in Q4 2020 and held it in 16 quarters. The position peaked at $2.1M in Q3 2021. 33 funds tracked by Wall St. Rank hold ALGS as of Q3 2025.

  • Charles Schwab reported no remaining Aligos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 25,398 Aligos Therapeutics shares in Q3 2025, an estimated $183K.
  • Charles Schwab first reported a position in Aligos Therapeutics in Q4 2020 and held it in 16 quarters.
  • Charles Schwab's Aligos Therapeutics position peaked at $2.1M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.